Kura Oncology Reports $22.8 Million in Q3 Revenue and $70.2 Million Net Loss

Kura Oncology reported third-quarter 2026 revenue of $22.8 million, including $13.9 million in KOMZIFTI product revenue, and a net loss of $70.2 million. KOMZIFTI prescriptions and new patient starts increased sequentially, while the company advanced its frontline AML program and reached FDA alignm…